KIT Inhibitors Lead to Shift in Treatment of Systemic Mastocytosis

September 26, 2023Pankit Vachhani, MDPrithviraj Bose, MDThe hematologic neoplasm systemic mastocytosis is marked by the clonal proliferation of mast cells in the skin, bone marrow, gastrointestinal tr

Updated on: October 24,2023

KIT Inhibitors Lead to Shift in Treatment of Systemic Mastocytosis

September 26, 2023Pankit Vachhani, MDPrithviraj Bose, MDThe hematologic neoplasm systemic mastocytosis is marked by the clonal proliferation of mast cells in the skin, bone marrow, gastrointestinal tr

Updated on:October 24,2023

Deaths from advanced lung cancer have dropped significantly since immunotherapy became standard-of-care

byWileyCredit: Unsplash/CC0 Public DomainSince the first immunotherapy drug to boost the body's immune response against advanced lung cancer was introduced in the United States in 2015, surv

Updated on: August 27,2024

Deaths from advanced lung cancer have dropped significantly since immunotherapy became standard-of-care

byWileyCredit: Unsplash/CC0 Public DomainSince the first immunotherapy drug to boost the body's immune response against advanced lung cancer was introduced in the United States in 2015, surv

Updated on:August 27,2024

AI in Oncology: Balancing Innovation with Ethical Oversight

Updated on: July 21,2025

AI in Oncology: Balancing Innovation with Ethical Oversight

Updated on:July 21,2025

Scientists develop powerful AI algorithm to gain new insights into deadly glioblastoma

by Sylvester Comprehensive Cancer CenterThe SPHINKS network for the precision targeting of master kinases in glioblastoma. Credit: Antonio Iavarone, M.D.Scientists at Sylvester Comprehensive Cancer Ce

Updated on: December 27,2023

Scientists develop powerful AI algorithm to gain new insights into deadly glioblastoma

by Sylvester Comprehensive Cancer CenterThe SPHINKS network for the precision targeting of master kinases in glioblastoma. Credit: Antonio Iavarone, M.D.Scientists at Sylvester Comprehensive Cancer Ce

Updated on:December 27,2023

New study seeks hereditary causes of childhood cancer

byKarolinska InstitutetOverview of study design and study cohort. Credit:The Lancet Regional Health—Europe(2024). DOI: 10.1016/j.lanepe.2024.100881Follow-up and treatment of children

Updated on: April 28,2024

New study seeks hereditary causes of childhood cancer

byKarolinska InstitutetOverview of study design and study cohort. Credit:The Lancet Regional Health—Europe(2024). DOI: 10.1016/j.lanepe.2024.100881Follow-up and treatment of children

Updated on:April 28,2024

Obesity is increasing people's risk of cancer. Why?

by Nancy Fliesler,Children's Hospital BostonAcomposite image representing a dormant breast tumor in the mammary fat pad of an obese mouse that is recruiting new blood vessels. Credit:

Updated on: December 22,2023

Obesity is increasing people's risk of cancer. Why?

by Nancy Fliesler,Children's Hospital BostonAcomposite image representing a dormant breast tumor in the mammary fat pad of an obese mouse that is recruiting new blood vessels. Credit:

Updated on:December 22,2023

Pathogenesis to management of hepatocellular carcinoma

by Impact JournalsMolecular pathways and targeted therapeutics in hepatocellular carcinoma. Abbreviations: APC: antigen presenting cell; AXL is a cell surface receptor tyrosine kinase, part of the TAM

Updated on: December 22,2023

Pathogenesis to management of hepatocellular carcinoma

by Impact JournalsMolecular pathways and targeted therapeutics in hepatocellular carcinoma. Abbreviations: APC: antigen presenting cell; AXL is a cell surface receptor tyrosine kinase, part of the TAM

Updated on:December 22,2023

FDA Approves Lymphir: A New Hope for CTCL Patients

The U.S. Food and Drug Administration (FDA) had approved Lymphir (denileukin diftitox-cxdl), a novel immunotherapy for the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.

Updated on: August 12,2024

FDA Approves Lymphir: A New Hope for CTCL Patients

The U.S. Food and Drug Administration (FDA) had approved Lymphir (denileukin diftitox-cxdl), a novel immunotherapy for the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.

Updated on:August 12,2024

Prozac fights deadly childhood brain cancer

by Hayley Jarvis,Brunel UniversityKiller T cells surround a cancer cell. Credit: NIHThe anti-depressant drug Prozac could be used to tackle one of the deadliest childhood tumours and possibly ot

Updated on: December 22,2023

Prozac fights deadly childhood brain cancer

by Hayley Jarvis,Brunel UniversityKiller T cells surround a cancer cell. Credit: NIHThe anti-depressant drug Prozac could be used to tackle one of the deadliest childhood tumours and possibly ot

Updated on:December 22,2023

Scientists uncover key mechanism linking microtubules and chemotherapy, enhancing cancer drug efficacy

Updated on: March 17,2025

Scientists uncover key mechanism linking microtubules and chemotherapy, enhancing cancer drug efficacy

Updated on:March 17,2025

When combined, a novel LSD1 inhibitor and an existing therapy enhance each other's anti-cancer effects

by Jaclyn Dunne,Medical University of South CarolinaGraphical abstract. Credit:European Journal of Medicinal Chemistry(2022). DOI: 10.1016/j.ejmech.2022.114818A Medical University of

Updated on: December 20,2023

When combined, a novel LSD1 inhibitor and an existing therapy enhance each other's anti-cancer effects

by Jaclyn Dunne,Medical University of South CarolinaGraphical abstract. Credit:European Journal of Medicinal Chemistry(2022). DOI: 10.1016/j.ejmech.2022.114818A Medical University of

Updated on:December 20,2023

Olaparib maintenance extends PFS by estimated three years in advanced ovarian cancer

byEuropean Society for Medical OncologyTwo-year maintenance therapy with olaparib, a PARP (poly ADP ribose polymerase) inhibitor, olaparib, led to a substantial, unprecedented improvement in pro

Updated on: December 18,2023

Olaparib maintenance extends PFS by estimated three years in advanced ovarian cancer

byEuropean Society for Medical OncologyTwo-year maintenance therapy with olaparib, a PARP (poly ADP ribose polymerase) inhibitor, olaparib, led to a substantial, unprecedented improvement in pro

Updated on:December 18,2023